Healthcare Guide

Anticoagulants Industry 2018: Forecast Up-to 2027, SWOT Evaluation and Development Status

Lehdistötiedote   •   Tammi 13, 2020 08:24 EET

​The global Anticoagulants Market is estimated to grow at CAGR above 7.9% over the forecast time frame 2018-2027 and reach the market value around $39 billion by 2027. The report is titled “Anticoagulants Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 – 2027” and it intends to offer a comprehensive overview of the market to its stakeholders.

To keep pace with the increasing demand, the leading organizations are investing in various research and development initiatives. This, coupled with government support, implementation of policies supporting expansion of pharmaceutical and healthcare industries, and accessibility to improved reimbursement policies are supporting the growth of this market.

The report offers a bird’s eye view of the Anticoagulants Market, gauging its growth trajectory over the years. It presents insights into key factors boosting the markets, besides the ones restricting its growth. The report also highlights hidden opportunities for the market besides revealing the key restraints. It is therefore intended to help market players determine their growth strategies and make informed decisions pertaining to potential investments.

Download Free Sample Report Pages@ https://www.acumenresearchandconsulting.com/request-sample/1201

The report includes information obtained from various sources from within the industry. Latest statistics from international organizations are considered while compiling this study. In addition to this, opinions from experts are taken to offer refined growth forecasts. Information compiled in the study is derived with primary and secondary research methods. Besides this, industry-leading analytical tools are used examine information received. The report uses price trend analysis, qualitative and quantitative analysis to evaluate prevalent market trends.

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2018. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2018 to 2027. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

List of Companies

The report lists down some of the leading companies operating in this market. The market share of the global Anticoagulants Market is dominated by companies like Bristol-Myers Squibb Company, Pfizer, Inc., Bayer Healthcare, Sanofi, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., and Daiichi Sankyo Company Limited.

The policies adopted by these companies are studied in detail. Furthermore, the report offers insights into their product portfolio, pricing strategies, strategic collaborations, mergers and acquisitions, among others.

SWOT Analysis is conducted on the companies listed to study their strengths and weaknesses. Furthermore, the analysis offered insights into opportunities and threats present in the market for these companies. A comparative analysis between these companies is intended to highlight the most successful strategies adopted by these companies. Doing so, the report offers recommendations for growth to companies operating in the market. It is thus conducted to help companies, irrespective of their size, access relevant information.

Regional Outlook

The report segments the global Anticoagulants Market into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa in terms of region. According to studies, developed economies are likely to offer stability to the market. The higher rate of adoption of latest technologies and the presence of a sophisticated healthcare network will augment growth in the market in North America. In Europe as well the market will gain from favourable government policies.

In the last couple of years, the investment towards expanding healthcare infrastructure has greatly surged in emerging economies of Asia Pacific and Latin America. This, coupled with the rising awareness about various diseases and the treatment available for the same will support growth in emerging countries.

Key Segments

The report segments the market into various categories. The leading segments within each category are identified in the report. Furthermore, it calculates market share that these segments hold. Factors enabling growth in this segments are studied in detail. The report also reveals the factors that may restrain the market growth in these categories.

Market Segmentation

Market By Route of Administration

  • Oral
  • Injectable

Market By Drug Class

  • Factor XA Inhibitors (NOAC/DOAC)
  • Heparins
  • Direct Thrombin Inhibitors
  • Vitamin K Antagonists

Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Market By Indication

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Atrial Fibrillation
  • Heart Attack

Market Regional Analysis:

Based on the regions, the global Anticoagulants Market is segmented into -North America (US and Canada), Europe (UK, Germany, France, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific), Latin America (Mexico, Brazil and Rest of Latin America), Middle East & Africa (GCC, South Africa and Rest of MEA).

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Anticoagulants
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Anticoagulants Market By Route of Administration
1.2.2.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.2.2. Global Anticoagulants Market Revenue Share By Route of Administration in 2017
1.2.2.3. Oral
1.2.2.4. Injectable
1.2.3. Anticoagulants Market By Drug Class
1.2.3.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Global Anticoagulants Market Revenue Share By Drug Class in 2017
1.2.3.3. Factor XA Inhibitors (NOAC/DOAC)
1.2.3.4. Heparins
1.2.3.5. Direct Thrombin Inhibitors
1.2.3.6. Vitamin K Antagonists
1.2.4. Anticoagulants Market By Distribution Channel
1.2.4.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.4.2. Global Anticoagulants Market Revenue Share By Distribution Channel in 2017
1.2.4.3. Hospital Pharmacies
1.2.4.4. Retail Pharmacies
1.2.4.5. Online Pharmacies
1.2.5. Anticoagulants Market By Indication
1.2.5.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.5.2. Global Anticoagulants Market Revenue Share By Indication in 2017
1.2.5.3. Deep Vein Thrombosis (DVT)
1.2.5.4. Pulmonary Embolism (PE)
1.2.5.5. Atrial Fibrillation
1.2.5.6. Heart Attack
1.2.6. Anticoagulants Market by Geography
1.2.6.1. Global Anticoagulants Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Anticoagulants Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Anticoagulants Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Anticoagulants Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Anticoagulants Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Anticoagulants Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Anticoagulants Major Manufacturers in 2017

CHAPTER 4. ANTICOAGULANTS MARKET BY ROUTE OF ADMINISTRATION

4.1. Global Anticoagulants Revenue By Route of Administration
4.2. Oral
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Injectable
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTICOAGULANTS MARKET BY DRUG CLASS

5.1. Global Anticoagulants Revenue By Drug Class
5.2. Factor XA Inhibitors (NOAC/DOAC)
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Heparins
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Direct Thrombin Inhibitors
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Vitamin K Antagonists
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL

6.1. Global Anticoagulants Revenue By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. ANTICOAGULANTS MARKET BY INDICATION

7.1. Global Anticoagulants Revenue By Indication
7.2. Deep Vein Thrombosis (DVT)
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Pulmonary Embolism (PE)
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Atrial Fibrillation
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Heart Attack
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. NORTH AMERICA ANTICOAGULANTS MARKET BY COUNTRY

8.1. North America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Anticoagulants Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. EUROPE ANTICOAGULANTS MARKET BY COUNTRY

9.1. Europe Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 10. ASIA-PACIFIC ANTICOAGULANTS MARKET BY COUNTRY

10.1. Asia-Pacific Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. LATIN AMERICA ANTICOAGULANTS MARKET BY COUNTRY

11.1. Latin America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million
11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million))
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. MIDDLE EAST ANTICOAGULANTS MARKET BY COUNTRY

12.1. Middle East Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 13. AFRICA ANTICOAGULANTS MARKET BY COUNTRY

13.1. Africa Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
13.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
13.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Bristol-Myers Squibb Company
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Pfizer, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Bayer Healthcare
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Sanofi
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Boehringer Ingelheim International GmbH
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Johnson & Johnson Services, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Daiichi Sankyo Company Limited
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ ​

Contact Us:

Acumen Research and Consulting

Email: sales@acumenresearchandconsulting.com

Phone: +1 407 915 4157

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.